163 related articles for article (PubMed ID: 18066548)
1. Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide.
Formelli F; Cavadini E; Luksch R; Garaventa A; Villani MG; Appierto V; Persiani S
Cancer Chemother Pharmacol; 2008 Sep; 62(4):655-65. PubMed ID: 18066548
[TBL] [Abstract][Full Text] [Related]
2. Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients.
Formelli F; Cavadini E; Luksch R; Garaventa A; Appierto V; Persiani S
Cancer Chemother Pharmacol; 2010 Oct; 66(5):993-8. PubMed ID: 20532509
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.
Garaventa A; Luksch R; Lo Piccolo MS; Cavadini E; Montaldo PG; Pizzitola MR; Boni L; Ponzoni M; Decensi A; De Bernardi B; Bellani FF; Formelli F
Clin Cancer Res; 2003 Jun; 9(6):2032-9. PubMed ID: 12796365
[TBL] [Abstract][Full Text] [Related]
4. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).
; Villablanca JG; Krailo MD; Ames MM; Reid JM; Reaman GH; Reynolds CP
J Clin Oncol; 2006 Jul; 24(21):3423-30. PubMed ID: 16849757
[TBL] [Abstract][Full Text] [Related]
6. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
Maurer BJ; Kalous O; Yesair DW; Wu X; Janeba J; Maldonado V; Khankaldyyan V; Frgala T; Sun BC; McKee RT; Burgess SW; Shaw WA; Reynolds CP
Clin Cancer Res; 2007 May; 13(10):3079-86. PubMed ID: 17505011
[TBL] [Abstract][Full Text] [Related]
7. P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.
Lopez-Barcons L; Maurer BJ; Kang MH; Reynolds CP
Int J Cancer; 2017 Jul; 141(2):405-413. PubMed ID: 28340497
[TBL] [Abstract][Full Text] [Related]
8. Enhanced anti-neuroblastoma activity of a fenretinide complexed form after intravenous administration.
Carosio R; Pistoia V; Orienti I; Formelli F; Cavadini E; Mangraviti S; Montaldo PG; Ognio E; Emionite L; Zuccari G
J Pharm Pharmacol; 2012 Feb; 64(2):228-36. PubMed ID: 22221098
[TBL] [Abstract][Full Text] [Related]
9. Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids.
Cuperus R; Tytgat GA; Leen R; Brites P; Bras J; Caron HN; Van Kuilenburg AB
Int J Oncol; 2008 May; 32(5):1011-9. PubMed ID: 18425327
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
Maurer BJ; Kang MH; Villablanca JG; Janeba J; Groshen S; Matthay KK; Sondel PM; Maris JM; Jackson HA; Goodarzian F; Shimada H; Czarnecki S; Hasenauer B; Reynolds CP; Marachelian A
Pediatr Blood Cancer; 2013 Nov; 60(11):1801-8. PubMed ID: 23813912
[TBL] [Abstract][Full Text] [Related]
11. Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1.
Villani MG; Appierto V; Cavadini E; Valsecchi M; Sonnino S; Curley RW; Formelli F
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6265-75. PubMed ID: 15448016
[TBL] [Abstract][Full Text] [Related]
12. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
Cooper JP; Reynolds CP; Cho H; Kang MH
Exp Biol Med (Maywood); 2017 Jun; 242(11):1178-1184. PubMed ID: 28429653
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of anti-tumour effects of oral fenretinide (4-HPR) in rats with human neuroblastoma xenografts.
Ponthan F; Lindskog M; Karnehed N; Castro J; Kogner P
Oncol Rep; 2003; 10(5):1587-92. PubMed ID: 12883745
[TBL] [Abstract][Full Text] [Related]
14. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
Formelli F; Carsana R; Costa A; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M
Cancer Res; 1989 Nov; 49(21):6149-52. PubMed ID: 2529028
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group.
Villablanca JG; London WB; Naranjo A; McGrady P; Ames MM; Reid JM; McGovern RM; Buhrow SA; Jackson H; Stranzinger E; Kitchen BJ; Sondel PM; Parisi MT; Shulkin B; Yanik GA; Cohn SL; Reynolds CP
Clin Cancer Res; 2011 Nov; 17(21):6858-66. PubMed ID: 21908574
[TBL] [Abstract][Full Text] [Related]
16. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line.
Appierto V; Cavadini E; Pergolizzi R; Cleris L; Lotan R; Canevari S; Formelli F
Br J Cancer; 2001 Jun; 84(11):1528-34. PubMed ID: 11384104
[TBL] [Abstract][Full Text] [Related]
17. Fenretinide-polyvinylalcohol conjugates: new systems allowing fenretinide intravenous administration.
Orienti I; Zuccari G; Bergamante V; Carosio R; Gotti R; Cilli M; Montaldo PG
Biomacromolecules; 2007 Oct; 8(10):3258-62. PubMed ID: 17883277
[TBL] [Abstract][Full Text] [Related]
18. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
[TBL] [Abstract][Full Text] [Related]
19. N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase.
Wang H; Maurer BJ; Reynolds CP; Cabot MC
Cancer Res; 2001 Jul; 61(13):5102-5. PubMed ID: 11431347
[TBL] [Abstract][Full Text] [Related]
20. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
Perucca E; Cloyd J; Critchley D; Fuseau E
Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
